Market Overview

Celgene Reports Q2 Earnings Beat, Raises Guidance

Share:
Celgene Reports Q2 Earnings Beat, Raises Guidance

Celgene (NASDAQ: CELG) reported second-quarter earnings of $2.86 per share, which beat the analyst consensus estimate of $2.63 by 8.75%. This is a 32.41% increase over earnings of $2.16 per share from the same period last year.

The company reported quarterly sales of $4.4 billion, which beat the analyst consensus estimate of $4.23 billion by 4.02%. This is a 15.36% increase over sales of $3.814 billion the same period last year.

Celgene also raised fiscal year 2019 guidance: adjusted EPS from $10.60-$10.80 to $10.65-$10.85 versus a $10.73 estimate; and sales from $17 billion-$17.2 billion to $17.2 billion-$17.4 billion versus a $17.11 billion estimate.

Celgene shares are trading up 1.09% at $94 in Tuesday’s pre-market session. The stock has a 52-week high of $98.97 and a 52-week low of $58.59.

Related Links:

The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus

Mylan Reports Q2 Earnings Beat

Posted-In: Earnings News Guidance Top Stories Best of Benzinga

 

Related Articles (CELG)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

5 Tips For Mortgage Approval

Altria Group Reports Q2 Earnings Beat